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1. Introduction 
Tobacco and alcohol are well-established risk factors for head and neck squamous cell 
carcinomas (HNSCC), but it can also develop in individuals not exposed to them. However, 
only a small proportion of tobacco exposed individuals have developed HNSCC, and there 
is an emerging tumoral population who lack exposure to these mentioned risk factors, 
suggesting that others factors can play a role in head and neck carcinogenesis. Over the past 
two decades, the role of high-risk human papilloma virus (HPV) has been studied through 
several studies worldwide, and data supporting its role as a causative agent in the 
development and progression of a subset of HNSCC has been controversial, with 
considerable variability in frequency depending on the population studied, tumor 
localization, quality of samples and technical resources utilized for HPV detection. As is the 
case in cervical and anogenital carcinomas, the most frequently detected high-risk HPVs in 
HNSCC are the 16 and 18 genotypes. The tonsils and oropharynx are the specific sites 
associated with higher risk of HPV oncogenic transformation, and investigations suggest 
that HPV infection in these anatomic sites is an independent risk factor for carcinogenesis. 
The establishment and maintenance of HPV genomes in the squamous epithelium and 
HPV-related HNSCC cancer is believed to be originated by oncogenic potential of HPV 
integration into host DNA genome and their ability to manipulate cell cycle regulators, 
resulting in deregulated expression of oncoproteins such as E6, which promotes degradation 
of the tumor suppressor protein p53, allowing cells to evade cell cycle checkpoints, and also 
E7, which binds to retinoblastoma protein (pRb) and could promote the entrance in S1 phase 
of cell cycle, leading to disruption of normal cell cycle controls. Following cell division, 
infected cells leave the basal layer, migrate towards the suprabasal regions and begin to 
differentiate. Increased understanding of cervical pathogenesis has led to confirmation of 
HPV as an etiological agent for cancers and consequently to the development of preventive 
vaccines targeting HPV antigens for the control of cervical cancer. The HPV vaccine was 
developed as a result of the achievement of core technologies able to produce virus-like 
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particles (VLPs). The recombinant DNA was used to generate VLPs able to mimicking the 
natural virus and eliciting high-titers of virus neutralizing antibodies. With the progress 
through advanced stages of clinical trials and further exploration of combinatorial strategies, 
there is a great promise for significant advances also in the field of therapeutic HPV vaccine 
development. We recently conducted a study with the purpose of investigate the presence 
of HPV in a Brazilian population sample of HNSCC patients. In cases with positive 
specimens, the analysis was extended to clinicopathological profile characterization and to 
the correlation between patient survival and HPV DNA presence in primary HNSCC 
tumors as well as in their corresponding matched samples of recurrences, lymph nodal 
metastasis and necropsies. This research was conducted on the medical files of patients with 
head and neck tumors, the histopathological diagnosis of HNSCC was confirmed and 
paraffin-embedded specimens were selected for investigation. Moreover, in this chapter we 
discuss the current status of HPV vaccines as well as the main associated factors that 
interfere on establishment of strategies that better could act to control the infections and 
development of malignant neoplasias. 
2. Historical aspects 
One of the earliest manifestations of HPV infection was observed during an autopsy 
performed in 1974 on the embalmed body of an ancient Egyptian worker from 12th century 
BC who had a wart on the sole of his foot (Onon, 2010, as cited in McCaffery, 1974). The 
Ancient Greeks and Romans had already recognized that genital warts could be sexually 
transmitted (Onon, 2010, as cited in Claude Moore Health Sciences Library, 2011); however, 
the viral origin of warts was only confirmed in the 19th century (Onon, 2010, as cited in 
Ciuffo, 1907). By the early 1970s, the herpes simplex virus type 2 was thought to be the 
sexually transmitted etiologic factor that was responsible for cervical cancer (Onon, 2010, as 
cited in Klein, 1973). However, Harald Zur Hausen, a young German professor of virology, 
was not convinced of this hypothesis, and in 1976, he postulated that papilloma viruses play 
a role in cancer of the cervix. Papilloma viruses have now been well established as the cause 
of almost 100% of cervical carcinomas (Kumaraswamy & Vidhya, 2011).  
The link between HPV and HNSCC was first studied by Syrjänen et al. (1983) in a light 
microcopy examination of 40 biopsy specimens from oral squamous cell carcinomas 
(OSCC), when the authors observed changes that are characteristic of HPV infection in 16 of 
the lesions. Recently, several studies have addressed the presence and prevalence of HPV in 
these types of tumors (Kumaraswamy & Vidhya, 2011). However, although the discovery of 
HPV has suggested that the virus may be a possible etiologic factor of oral pre-cancer and 
cancer, this association has not been as consistent as in cervical cancers. 
3. Head and neck cancer 
Head and neck malignancies compose a heterogeneous group and are believed to originate 
from sequential mutations that can occur as a consequence of progressive genetic instability 
and⁄or environmental factors, such as tobacco and alcohol consumption. These pathologies 
include a number of different types of cancer that arise from a variety of sites in the upper 
aerodigestive tract. Analysis of these tumors has revealed a heterogeneous neoplastic 
process that involves numerous sites with unique sets of epidemiologic, histopathologic, 
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and treatment considerations. Approximately 40% of head and neck cancers occur in the 
oral cavity, 15% occur in the pharynx, 25% occur in the larynx and the remaining tumors 
occur in other sites (Dobrossy, 2005). The most frequent histological type is the squamous 
cell carcinoma, which occurs in over 95% of cases. Squamous cell carcinomas originate from 
the epithelial surface of the oral cavity, oropharynx, hypopharynx, and larynx and affect 
approximately 500.000 patients worldwide each year (Popović et al., 2010). Low survival 
rates have been presented across several studies worldwide and reflect the need for more 
careful attention to HNSCCs. Because the mortality rates have essentially remained 
unchanged over the last several decades, considerable interest lies in discovering prognostic 
markers to guide therapeutic planning. 
4. HPV 
Papillomaviruses are a family of pathogens that infect exclusively the epithelial tissues of 
amphibians, reptiles, birds and mammals (Franceschi, 2007). The viruses are grouped 
according to the anatomic site of infection and their preference for either cutaneous or 
mucosal squamous epithelium. The cutaneous types, or beta papillomaviruses, are usually 
found in the general population and cause common warts. In contrast, the alpha, or 
mucosotropic, papillomaviruses have been implicated in mucosal infections (Snow & 
Laudadio, 2010; Vidal & Gillison, 2008). The mucosotropic group of human papillomavirus 
comprises 15 species and infects the anogenital tract, upper aerodigestive tract and other 
head and neck mucosa. Because they are sexually transmitted and play important roles in 
diseases, these viruses have received much attention and research and clinical investment 
(Chow et al., 2010).  
The HPV genome is a small (55 nm), double-stranded DNA molecule of approximately 8.000 
base pairs, and it contains three identified regions: a late region (L) containing two genes, L1 
and L2, which encode the viral capsid proteins; an early region (E) encoding proteins 
involved in viral DNA replication and the control of viral transcription, such as E1 and E2, 
and the main transforming genes E6, E7 and E5; and a long control region (LCR), found 
between the L and E regions, which contains several binding sites for nuclear and viral 
transcriptional factors, promoter sequences and an open reading frame (ORF) region 
(Fernandes et al., 2009). The early and late gene regions are both protein-encoding, but the 
LCR is non-encoding. The LCR possesses numerous binding sites for many repressors and 
activators of transcription, suggesting that this region may play a role in determining the 
range of hosts for specific HPV types (Tanzi et al., 2009). 
Traditionally, the papillomaviruses have been classified by type and by the ORF L1 region 
because this region is greatly conserved along the viral genome and has been used to detect 
new types of papillomavirus for more than 15 years. However, other genomic regions can 
also be used (i.e., E6 and E7). Each genotype is characterized as being more than 10% 
different from all other genotypes in their specific regions of DNA sequences. Differences of 
2% to 10% define a subtype and less than 2% define a viral variant. Closely related types 
(approximately 80–90% identical) are classified as members of the same species, and they 
tend to share important biological properties, such as tissue tropism, disease manifestation, 
and pathogenicity (Chow et al., 2010; De Villiers et al., 2004). Currently, well over 120 
different genotypes of HPVs have been isolated, sequenced and phylogenetically 
characterized. Thirty-three percent of these 120 genotypes are known to infect the human 
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genital tract (De Villiers et al., 2004; Hennessey et al., 2009, as cited in Longworth & Laimins, 
2004; Martinez et al., 2007). Mucosotropic HPVs can be further classified into non-oncogenic, 
or low-risk, types or as potentially oncogenic, or high-risk, types. Mucosal and genital HPVs 
can be divided into low-risk (HPVs 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81) and high-risk 
(HPVs 16, 18, 31, 33, 35, 51, 52) types according to their presence in malignant lesions (Bosch 
et al., 2002; Muñoz et al., 2003). HPVs 31, 33, 35, 51 and 52 are sometimes regarded as 
“intermediate risk” viruses because they are more common in mild or severe dysplastic 
lesions than in carcinomas (Fernandes et al., 2009). 
The late region units L1 and L2 encode for viral capsid proteins during the late stages of 
virion assembly (Park et al., 1995). The protein encoded by L1 is highly conserved among 
different papilloma virus species; accordingly, antibodies against the bovine papilloma virus 
have been used to identify HPV capsid proteins in human tissues. The minor capsid protein 
encoded by L2 has more sequence variations than that of the L1 protein; hence, the L2 
protein has been a source of antigen for specific types of HPV antibodies. The E1 and E2 
region units encode proteins that are vital for extrachromosomal DNA replication and 
completion of the viral life cycle. The E2 protein is modular and contains an N-terminal 
activation domain that is important for viral transcription and replication and for interaction 
with host chromosomes during mitosis. The E2 region also encodes two proteins, one of 
which inhibits transcription of the early region, while the other increases the transcription of 
the early region (Ward et al., 1989). The HPV E5 proteins are small, extremely hydrophobic, 
and located mainly at the endosomal membranes, Golgi apparatus and, to a lesser extent, 
the plasma membranes. Moreover, E5 proteins are traditionally known to interact with the 
transmembrane domain of the EGF receptor and to modulate its concentration and 
phosphorylation (Villa et al., 2002). When present, E5 interacts with various transmembrane 
proteins, such as the EGF receptors, platelet-derived growth factor β, and colony stimulating 
factor-1 (Talbert-Slagle & DiMaio, 2009).  
The multiplicity of functions of the three small papillomavirus oncoproteins, E5, E6 and E7, 
continues to be amazing. Specifically, more than a dozen protein-protein interactions 
between E6 and cellular proteins have been published (Villa et al., 2002). In the protein-
encoding regions, the E6 and E7 ORF are considered to play the most important roles. These 
units encode for oncoproteins that allow viral replication and the immortalization and 
transformation of the cell that host the HPV DNA (Doorbar et al., 1991). 
Mucosal high-risk E6 proteins are best known for their ability to associate with the cellular 
tumor suppressor p53. The association of E6 with p53 leads to degradation of p53 via 
recruitment of an ubiquitin ligase, E6-AP, and results in the inhibition of the transcriptional 
regulatory activities of the p53 protein in tissue culture cells (Gonzalez et al., 2001; Jones & 
Münger, 1997). Similarly, the high-risk HPV E7 proteins are best known for their ability to 
associate with the cellular tumor suppressor pRb, and this association can promote pRb 
degradation (Jones & Münger, 1997) through a proteasome-mediated pathway that disrupts 
the capacity of pRb to bind and inactivate functionally cellular E2F transcription factors 
(Gonzalez et al., 2001). In addition to binding pRb, high-risk E7 proteins can bind to other 
pocket proteins (p107 and p130) that are related to pRb and interact with different members 
of the E2F family of transcription factors (Dyson et al., 1992). The inactivation of pocket 
proteins by E7 is necessary but not sufficient to elicit the transforming potential of E7 
(Phelps et al., 1992). High-risk E7 is also purported to complex with cyclins (Dyson et al., 
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1992) and to inactivate the cyclin associated kinase inhibitors p21 and p27 (Jones & Münger, 
1997). Thus, E7 can associate with and/or alter the activities of multiple cellular factors that 
normally contribute to the regulation of the cell cycle. The oncogenic properties of E6 and E7 
and their effects on p53 and pRb have provided the general basis for further investigations 
of the role of HPV in carcinogenesis. The research examining the actions of these two 
oncoproteins has shown how they can subvert key cell cycle and regulatory processes, such 
as cyclins, cyclin-dependent kinases (CDKs) and cyclin-dependent kinase inhibitors (CDIs), 
to transform and immortalize the host cells (Southern & Herrington, 2000). 
Proving the importance of p53 and pRb in cell cycle progression, the repression of HPV 16 
E6 and E7 expression by dual shRNA transfection has been shown to be capable of restoring 
the p53 and pRb tumor suppressor pathways and activating apoptosis (Psyrri et al., 2009, 
Rampias et al., 2009). Thus, the demonstration of this tumor suppressor inactivation by the 
E6 and E7 HPV oncoproteins has provided a basic explanation for how the high-risk HPV 
types exert their oncogenic effects on cervical cells. 
5. The route of cellular conquest by HPV  
Unlike other viruses, HPV does not infect or replicate in antigen-presenting cells of the 
epithelium nor induce cell lysis, so there is no chance for antigen-presenting cells to present 
antigens derived from the virion to the immune system. Despite the observation that more 
than 50% of infections present seroconversion in the patients, the production of antibodies 
usually occurs only months after the initial infection (Vidal & Gillison, 2008, as cited in 
Tindle, 2002). The life cycle of papillomaviruses is closely tied to the epithelial 
differentiation process. Infection occurs exclusively in squamous epithelial cells 
(keratinocytes) with preference for the keratinocyte stem cell as the initial target of HPV 
infection (Vidal & Gillison, 2008). The route of entry for HPV infection is microtraumas or 
small wounds in the skin or mucosal surface. These breaks in the epithelial surface allow the 
virus to access and persist in the nuclei of infected basal layer cells of the epithelium. Until 
now, no single receptor has been definitively identified and established as being responsible 
for HPV entry. Some reports have suggested that a6 integrin may be a candidate receptor 
because it is expressed primarily during wound healing. The glycosaminoglycan heparin, a 
polysaccharide expressed on the cell surface, may also play a role in the attachment 
necessary for the initiation of HPV infection (Vidal & Gillison, 2008).  
HPV uses the host cell DNA machinery to maintain the production of viral progeny. This 
mechanism of viral-induced cell growth is very well known and is analogous to other 
viruses that disrupt the control of cell growth (Hebner & Laimins, 2006). Following cell 
division, as the basal cells divide into squamous epithelial cells, HPV establishes its DNA 
genome in the host cell nuclei, replicates and reaches a high copy number. Infected cells 
then leave the basal layer, migrate toward the suprabasal regions and begin to differentiate. 
In the basal layer phase, the HPV genome is maintained at a low copy number, providing a 
type of stock of viral DNA for further use in cell divisions. At the same time, ‘early’ viral 
genes (E5, E6 and E7) are expressed, resulting in enhanced proliferation of the infected cells 
and their lateral expansion. While the basal cells and viral DNA divide, some daughter cells 
may be maintained in the basal layers, whereas other daughter cells move toward the upper 
layers of the epithelium and begin to differentiate. During the process in which the infected 
cells enter into the suprabasal layers, the viral genome replicates to a higher copy number; 
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‘late’ viral gene (L1 and L2) expression is initiated; and structural proteins, as such capsid 
proteins, are formed. Subsequently, virions are assembled and released as the upper layer of 
epithelium is shed, as shown in Figure 1 (Fehrmann & Laimins, 2003; Scheurer et al., 2005; 
Vidal & Gillison, 2008). 
 
Fig. 1. Representation of normal and HPV-infected epithelium according to the cellular 
differentiation and the differentiation-dependent viral functions (Adapted from Fehrmann 
& Laimins, 2003). 
HPV replication occurs through two mechanisms. The first mechanism occurs in the basal 
layer cells where the viral genome is distributed to daughter cells. In this mechanism, viral 
genome integration ensures a persistent infection in the proliferative cells from the basal 
layer and is associated with a higher risk of malignant cellular transformation. In the second 
mechanism, which is known as episomal or vegetative, HPV replication occurs in the more 
differentiated layers of the epithelium and the integration of viral DNA into the host cell 
genome is not necessary. Despite the fact that the replication processes and gene expression 
are controlled by the cell differentiation process, much about this mechanism is still 
unknown, and cervical cancer serves as a model for understanding HPV pathogenesis in 
other sites, such as in head and neck cancers (Zur Hausen, 2002). During cervical infection, 
the viral genome frequently integrates into the host cell genome. This integration occurs 
preferentially at fragile sites. The integration of viral DNA most likely disrupts the E2 
coding region, causing the loss of the role of E2 in transcriptional control; therefore, the 
expression of the E6 and E7 oncoproteins becomes deregulated (Vidal & Gillison, 2008).   
In tonsillar carcinomas, the absence of integrated HPV DNA does not suppress the 
expression of viral oncogenes, indicating that viral DNA integration is not an essential step 
for carcinogenesis and that the virus continues to be present in an episomal form (Hebner & 
Laimins, 2006; Vidal & Gillison, 2008). The mechanism used by HPV to remain in cancer 
tissue as an episomal form and produce high copy numbers is still unclear. However, some 
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observations have shown that the oncoprotein E2 may serve as an ‘anchor’ that links 
episomal HPV to the cellular mitotic spindles (Psyrri et al., 2009).  
6. How does HPV reach the head and neck sites?  
Generational changes have occurred in sexual practices around the world, where the young 
people are having their first sexual experience at an earlier age, with greater numbers of 
sexual partners and with a higher probability of engaging in oral sex compared to 
individuals from earlier decades (Heck et al., 2010). These differences in sexual behavior can 
also be seen between patients with HPV-positive HNSCCs, especially among those with the 
high-risk type HPV-16 (Gillison et al., 2008).  
In oropharyngeal cancers (OPCs) that are positive for HPV, a frequent association with 
sexual behavior has been found (D’Souza et al., 2007). An investigation of more than 5000 
cases of head and neck cancer and more than 6000 control cases from 12 different countries 
has indicated that a history of six or more lifetime sexual partners and four or more oral sex 
partners increases the odds of developing OPC. In cancer at the base of tongue, this 
association was found among individuals who have two sexual partners compared to those 
with only one, while little evidence has indicated any association between sexual practice 
and cancers of the oral cavity or of the larynx. Additionally, an increased risk of tonsillar 
cancer is associated with a history of four or more oral sex partners (3-fold increased risk), 
age at sexual debut < 18 years among men (2-fold increased risk) and in husbands of women 
who presented cervical dysplasia or cancer (Lajer & Von Buchwald, 2010). In addition to 
oral sexual activity, open-mouthed kissing has been found to be associated with oral HPV 
infections. Because this practice is common among young people in many countries, it may 
contribute to HPV circulation and increase the risk of HPV infection among individuals who 
might not otherwise be exposed. The prevalence of HPV in control patients from the studies 
of oral cancer varies from 5% to 9%; however, the same sexual behaviors associated with 
HNSCC can increase the odds of HPV infection in this population. Interestingly, in patients 
with HNSCCs, heavier smoking and alcohol use is associated with risky sexual behaviors, 
but this association is not observed in control individuals without cancer (D’Souza et al., 
2009). 
No difference was noticed between men and women according the outcomes of oral sex or 
number of oral sex partners and lifetime sexual partners, and the prevalence of oral HPV 
was found to be similar between heterosexual and bisexual women. In contrast, the presence 
of oral HPV infection is unlikely in virgins and women who have sex with women, which 
suggests that oral HPV is more likely to be associated with sexual exposure to male partners 
than to female partners (Ragin et al., 2011). 
7. HPV and oral lesions 
In the oral cavity, 24 types of HPV (1, 2, 3, 4, 6, 7, 10, 11, 13, 16, 18, 30, 31, 32, 33, 35, 45, 52, 
55, 57, 59, 69, 72 and 73) have been associated with benign lesions and 12 types (2, 3, 6, 11, 
13, 16, 18, 31, 33, 35, 52 and 57) with malignant lesions (Bouda et al., 2000; Kojima et al., 
2002). The low-risk HPV types cause benign oral hyperplasias that are usually painless and 
non-ulcerated (Cleveland, 2011). Verruca vulgaris (caused by HPV 2, HPV 4 and other HPV 
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types) usually occurs on the lips, hard palate and gingiva. Condyloma acuminata or genital 
warts (caused by HPV 6 and HPV 11) may also affect the oral mucosa and are found more 
commonly on keratinized mucosa (Cleveland et al., 2011; D’Souza et al., 2007; Dayyani et al., 
2010). Notwithstanding, since the first report of the presence of HPV DNA in head and neck 
cancer, 65 high-risk types have been consistently detected at different sites; however, these 
types are specifically found in transcriptionally active tumor cells (Vidal & Gillison, 2008). 
According to data from a review, 99% of HPV infections in head and neck cancers are by 
high-risk types 16, 18, 31 and 33 (Kreimer et al., 2005). Additionally, several others HPV 
types (6, 11, 35, 45, 51, 52, 56, 58, 59 and 68) have rarely been detected in head and neck 
cancer. Infection with HPV 33 accounts for up to 10% of positive head and neck cancers; 
however, the HPV 16 type is by far the most common type detected in head and neck cancer 
(Fakhry et al., 2008; Kreimer et al., 2005; Snow & Laudadio, 2010), and oropharyngeal 
tumors are more likely to have HPV 16 than other types at head and neck sites. The 
genotype 16 accounts for 78% to 100% of positive oropharyngeal cases, while HPV-18 
accounts for only 1% of cases (Kreimer et al., 2005). Seropositivity for HPV 16 has a greater 
association with an increased risk of OPC (OR = 14.4) than with the development of oral 
cavity cancer (OR = 3.6). This association is particularly strong in individuals without a 
history of smoking or drinking (OR = 33.6) (Hennessey et al., 2009). An interesting 
prevalence profile of the HPV types has been observed in some investigations in the 
countryside of Sao Paulo state in Brazil, where a higher prevalence of HPV 18 than HPV 16 
was found in oral and cervical carcinomas. Furthermore, the presence of HPV 18 was found 
to be associated with metastasis to the lymph nodes and shorter patient survival (Guimarães 
et al., 2010; Lira et al., 2010; Mazon et al., 2011). 
The results from recent studies have suggested that some of these cancers, primarily those 
that originate in the oropharynx (and, more specifically, at the base of the tongue and the 
tonsils), are associated with high-risk HPV infection (Lopes et al., 2011). This association is 
strengthened by the fact that the same oncogenic HPV types detected in cervical carcinomas 
have been identified in head and neck cancers. In recent oral cancer guidelines published by 
the American Dental Association (ADA), HPV was recognized as a risk factor for OPCs, but 
whether HPV is also responsible for some oral cavity cancers was questioned (Rethman, 
2010). 
Several head and neck tumors have been analyzed for the presence of HPV, and HPV DNA 
has been found in different proportions of tumors from different head and neck sites 
(Kreimer et al., 2005; Syrjanen, 2005). Some evidence has indicated that some subtypes of 
HPV are linked to head and neck cancer, especially those arising from some oropharyngeal 
subsites (e.g., tonsil and the base of the tongue) (Gillespie et al., 2009). The overall HPV 
prevalence in HNSCC ranges from 3% to 40% and could vary more according to the specific 
site. HPV has been found in 4-80% of oral cancers, 15-85% of tonsillar cancers, 
approximately 24% of non-tumor site-specific HNSCC and 14-57% of OPCs (IARC, 2007; 
Kreimer et al., 2005; Machado et al., 2010; Syrjanen, 2005; Termine et al., 2008). Brazilian 
observations in the countryside of Sao Paulo state have found a low prevalence of HPV in 
tumors of the larynx (Miranda et al., 2009) and an increase in the presence of HPV DNA in 
oral cavity cancers during the past two decades (Lira et al., 2010; Mazon et al., 2011; Oliveira 
et al., 2008). The wide variation in HPV prevalence can be attributed to different detection 
techniques, small sample numbers, differences in the lesions and sampling techniques and 
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epidemiological characteristics of the populations studied (Feller et al., 2010). Among the 
many methods to detect HPV infections, both polymerase chain reaction (PCR) and in situ 
hybridization assays have been well validated. 
Because of the high sensitivity of the PCR assay, it may detect not only oncogenic infections 
but also productive infections, virions or laboratory artifacts, which are common problems 
in HPV screening for cervical cancer (Leemans et al., 2011). The following additional 
techniques can also provide data regarding the presence of HPV: light and electron 
microscopy, ELISA, gene expression by DNA microarray, Dot blot, Southern blot, hybrid 
capture and ligase chain reaction for probe amplification. Despite the existence of 
innumerable options for HPV detection in HNSCC, a standardization of procedures for 
routine application has yet to be developed (Feller et al., 2010; Kumaraswamy & Vidhya, 
2011; Snow & Laudadio, 2010). 
A global consensus exists regarding the increasing risk of OPCs with HPV, mainly in the 
tonsils and at the base of the tongue (Attner et al., 2010; Heck et al., 2010). A survey of the 
Surveillance, Epidemiology and End Results (SEER) database revealed that the incidence 
rates for HPV at the base of the tongue and in the tonsils increased by 2% and 4%, 
respectively, between 1973 and 2001 in younger US populations (ages 20-44 years). At the 
same time, the incidence in all other oral and pharyngeal sites remained constant or 
decreased (Gillespie et al., 2009). Other countries, such as Sweden, have seen a similar 
increase in the incidence of tonsil cancer from 1997-2002; HPV could be isolated in 23% of 
specimens in the 1970s, 28% in the 1980s, 57% in the 1990s and 68% in specimens since 2000 
(Hammarstedt et al., 2006). A review of 60 studies of HPV prevalence, which was published 
in 2005, observed an overall prevalence of 26% of HPV in HNSCCs, with a greater percent at 
the oropharynx (36%) (Kreimer et al., 2005). Similar numbers were obtained from the results 
of a recent meta-analysis that included more than 5000 patients. Among all HNSCCs, 22% of 
cases presented HPV infection, and the subgroup of OPCs presented a prevalence of 41% 
(Dayyani et al., 2010). In the USA, approximately 40-80% of OPC cases are associated with 
HPV, whereas in Europe, the proportion ranges from 90% in Sweden to 20% in populations 
that contain a great number of heavy smokers (Marur et al., 2010). 
Confirming the importance of HPV infection in HNSCC, the 2007 International Agency for 
Research on Cancer (IARC) monograph on HPV found sufficient evidence for HPV 
carcinogenicity in the oral cavity and oropharynx and limited evidence for HPV 
carcinogenicity in the larynx (IARC, 2007). Currently, the identification of distinct 
epidemiological profiles in HPV-positive and HPV-negative HNSCCs is possible. Although 
studies have shown no concordance regarding some of these epidemiological aspects, we may 
have to look at HPV-positive and HPV-negative HNSCCs in a separate manner in the future, 
including scientific, diagnostic, epidemiological and clinical aspects and the management of 
treatment. The main factors studied are heavy or no tobacco/marijuana exposure, heavy or 
mild alcohol consumption, poor or intact dentition, low or high oral sex exposure, age > 50 
years or < 45 years, lower or higher socioeconomic status and deceasing or increasing 
incidence (Gillespie et al., 2009). The epidemiological trend suggests that HPV-positive 
HNSCC occurs more often in younger patients (age < 50 years), which differs from the typical 
characteristics of head and neck cancer (which is more frequent in men above 40 years old). 
The tumors associated with the presence of HPV usually appear strawberry-like and exophytic 
on gross inspection and occur more frequently in the tonsil and the base of tongue with a 
basaloid aspect, poor differentiation and cystic changes within metastatic lymph nodes 
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(Gillespie et al., 2009). In addition, gene expression profiles are known to be different in HPV-
positive OPCs compared with HPV-negative cases (Lajer & Von Buchwald, 2010). 
8. HPV in oropharyngeal cancer 
The OPCs comprises tumors arising in posterior regions of oral cavity, and its incidence has 
been increasing, especially between individuals aged 40 to 55 years. It is accepted that a 
great part of OPCs, especially in lingual and palatine tonsils, are originated by HPV 
infection. Compared to non-contaminated individuals, the relative risk is 15- to 200- fold in 
HPV infected patients, and may not show a history of known risk factors for OPC, such 
tobacco and alcohol consumption, highlighting a different pattern for non-HPV-related OPC 
(Marur et al., 2008). Moreover, the presence of HPV is also associated to positive cervical 
lymph nodes of patients in different sites of HNSCCs, but mainly in oropharynx 
(Goldenberg et al., 2008; Lira et al., 2010; Machado et al., 2010). 
Although oral and oropharyngeal HPV infections are primarily sexually acquired, other 
methods of contamination such as mouth to mouth contact between partners and between 
family members, besides autoinoculation, are also potential routes where HPV infection of 
oropharyngeal sites can be established. As oral and oropharyngeal subclinical HPV infection 
is not uncommon, it is possible that the epithelium may serve as a reservoir of virus (Feller 
et al., 2010).  
The most common morphological presentation of HPV-related OPC is different of non-HPV 
tumors. The HPV OPCs usually are not associated with dysplasia of surface epithelium, 
show lobular growth, are usually infiltrated by lymphocytes and have prominent basaloid 
morphology. Two microscopic features of HPV-related OPCs are likely to cause diagnostic 
ambiguity. First, HPV-related HNSCC is customarily misperceived as a poorly 
differentiated carcinoma based on the immature appearance of the tumor cells. In point of 
fact, the appearance of the tumor cells closely emulates the appearance of the reticulated 
epithelium—the specialized epithelium lining the tonsillar crypts from which HPV-related 
cancers arise. Thus, HPV-related OPCs are in fact highly differentiated. Clinically, HPV-
related tumors present mostly at an early T stage, but show an advanced nodal stage, 
generally presenting as stage III or IV tumors, although HPV-related OPCs usually have a 
better prognosis when compared to non-HPV tumors. Despite the HPV-associated OPC 
patients have a relatively better disease-free survival rate, some individuals develop 
recurrence of their cancers after treatment and dies from recurrent disease. Based in this 
condition, screening tests could be beneficial for the detection of disease persistence or of 
early disease, using unique markers associated with HPV infection (Feller et al., 2010). 
9. HPV in laryngeal cancer 
The relative frequency of HPV genotypes in carcinoma of the larynx is still unknown; 
several studies have demonstrated variable frequencies ranging from 8 to 58.8% (Hobbs et 
al., 2006; Psyrri et al., 2008). The larynx forms of contamination and transmission of the virus 
are sometimes speculative. Infections of the larynx, pharynx and esophagus can occur, 
especially at birth when the newborn passes through the birth canal and comes in contact 
with the fluid-contaminated site. Together with oral-genital transmission, puerperal 
infection is one explanation for the presence of HPV in the oral cavity, larynx and esophagus 
(Zur Hausen, 1996).  
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The potential oncogenic importance of low-risk types of HPV in the development of laryngeal 
papillomas is well established, and the predominant types are HPV 6 and 11 (Herrero et al. 
2003; Madkan et al., 2007), which are pathogens of laryngeal papillomatosis. According to the 
clinical characteristics and natural history of disease, four different forms of laryngeal 
papillomas exist, namely isolated juvenile papillomatosis, juvenile multiple, adult and adult 
isolated multiple (Madkan et al. 2007; Torrente & Ojeda, 2007). More recently, this 
nomenclature has been replaced by recurrent respiratory papillomatosis (RRP), which more 
accurately describes the extent of the disease and its tendency to recur (Muenscher et al., 2008). 
Juvenile-onset laryngeal papillomas are associated with HPV transmitted by vertical 
transmission from a mother with active or latent anogenital infection. More than 30% of 
mothers with genital warts gave birth to children who developed juvenile-onset laryngeal 
papillomatosis. This disease occurs most commonly in first-born children and those who were 
delivered vaginally to young mothers with genital warts. Cases of children with laryngeal 
papillomatosis who were born by cesarean section are rare. The progression of papillomas is 
slow, causing the progressive symptoms of shortness of breath, persistent cough and 
dysphonia. Juvenile laryngeal papillomatosis affects both sexes equally. The most worrisome 
aspect of the disease is the spread of the virus thorough the tracheobronchial tree, progressing 
to pulmonary papillomatosis and often resulting in an uncontrollable and fatal infection. 
Another important event is the malignant transformation of laryngeal papillomas, which 
despite being a rare event, occurs in approximately 3-7% of cases.  
The laryngeal papillomas of adult onset generally affect individuals with a higher number 
of sexual partners and greater frequency of orogenital contacts. The oral-genital 
transmission hypothesis is based on the fact that laryngeal papillomatosis and genital warts 
have the same associated HPV infections (HPV 6 and 11). The area of transition from 
cuboidal and cylindrical epithelium in the larynx and uterine cervix may favor the 
occurrence of HPV in this location (Torrente & Ojeda, 2007).  
The premalignant lesions of the larynx are defined as morphologically altered tissue in which 
the occurrence of cancer is more likely than in apparently normal tissues. The detection of HPV 
DNA in premalignant lesions shows that HPV infection can be involved in the development of 
some lesions. Premalignant oral lesions usually develop as a result of several factors, such as 
tobacco and alcohol, and the synergistic interaction of HPV infection with these factors may 
play a role in the progression to cancer (Torrente & Ojeda, 2007). However, although HPV has 
been found in a large proportion of laryngeal cancers, more epidemiological and experimental 
studies are needed to clarify the role of HPV in laryngeal carcinomas. 
10. Interaction between traditional risk factors and HPV infection in HNSCCs  
Smoking and alcohol consumption are characteristics of patients with oral, oropharyngeal, 
hypopharyngeal, and laryngeal cancer. However, in the last 30 years, the presence of HPV 
associated with the increase in the incidence of HNSCCs at specific sites has suggested that 
the HPV infection can be a potential risk factor, independent of tobacco abuse and ethanol 
consumption (Blomberg et al., 2011; Chaturvedi et al., 2008; D’Souza et al., 2007; 
Hammarstedt et al., 2006; Klozar et al., 2010).  
Several clarifying findings have recently been made in the scene of HPV in the head and 
neck. The traditional prototype of an OSCC patient used to be an older man who had 
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smoked and consumed alcohol for many years. However, this profile no longer represents 
patients who are now diagnosed with oral cancer. The patients now are usually younger (< 
60 years) Caucasians with no history of smoking or alcohol drinking (D’Souza et al., 2007; 
Gillison et al., 2008). The main risk factors, tobacco and alcohol, have been supplanted by 
other risk factors associated with HPV and sexual behavior, which include the number of 
sexual partners, a history of oral-genital and oral-anal sex. As a biomarker, the detection of 
HPV infection is emerging as a powerful method for identifying oral cancer. The presence 
and progress of the disease affects the selection of patients for specific treatments and tumor 
surveillance (Westra, 2009, as cited in Begum et al., 2003).  
Whether the use of tobacco or alcohol and HPV are synergistic in the etiopathogenesis of 
oral and oropharyngeal cancers is not yet clear (Feller et al., 2010). Notably, many studies of 
HPV infection and exposure to tobacco have concluded that patients with tumors containing 
HPV DNA are characterized by moderate or no consumption of tobacco and alcohol, unlike 
individuals in the typical head and neck cancer patient population (D’Souza et al., 2007; 
Hafkamp et al., 2008; Klussmann et al., 2003). In research performed by Koch et al. (1999) a 
2-fold higher rate of HPV-associated tumors was observed in noncurrent smokers compared 
to current smokers, although the group classified as noncurrent smokers included both 
never and former smokers (Sinha et al., 2011). However, small sized groups, weak statistical 
evidence, and inconsistent definitions of smoking status could limit some of these studies. 
No consensus exists regarding the definition of current, never or former smokers or the 
criteria of light vs. heavy smoking (Sinha et al., 2011).  
In contrast, most of the studies that have noted a positive association between tobacco and 
HPV infection have had large sample sizes and adequate controls, which support consistent 
conclusions. A study that evaluated 201 cases of HNSCC using an ELISA assay to assess 
anti-HPV virus-like particles observed no interaction with alcohol in the oral cavity or 
oropharynx cancer, but a significant interaction between HPV and tobacco among 
oropharyngeal cases was obtained (Herrero et al., 2003; Smith et al., 2010). Other 
information provided by these studies is the influence of smoking intensity on disease 
survival. Heavy smoking of more than 20 pack-years has been associated with an increased 
hazard ratio of death (hazard ratio, 1.79) in patients with HPV-positive OPC compared to 
patients who smoke less than 20 pack-years (Gillison et al., 2009). 
Although much of our understanding of HPV in HNSCCs is based on the model of cervical 
cancer, the degree of interaction between smoking and HPV in this type of cancer is still not 
well known. Biologically, smoking can suppress the mediators of immune function, 
facilitating the persistence of HPV infection and the development of cancer (Sinha et al., 
2011). The DNA damage caused by smoking may impede the cell’s ability to recuperate 
from mutagenic insults; together with an increase in p53 mutations, this impairment can 
produce fragile sites or “hot spots” of DNA breakage, which facilitates the integration of the 
virus into the host DNA (Sinha et al., 2011). Thus, genetic or epigenetic alterations caused by 
tobacco have also been postulated to accelerate disease progression in HPV-infected 
individuals (Maxwell et al., 2010; Sinha et al., 2011).  
11. What can HPV tell us about prognosis and treatment?  
Due to locoregional recurrences, distant metastases and second primary tumors, no 
substantial improvement in survival has been observed in patients with HNSCCs in recent 
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decades (Leemans et al., 2011). Because multivariate analyses have pointed to HPV status as 
significant prognostic information in addition to the traditional established factors, the data 
suggest that HPV is the most important independent prognostic factor in HNSCC 
(Hannisdal et al., 2010; Lajer & Von Buchwald, 2010). HPV-infected HNSCCs have favorable 
prognoses upon treatment compared with HPV-negative tumors at a similar clinical stage 
(Leemans et al., 2011). Most investigations that have evaluated HPV infection and survival 
agree that HPV-positive patients have a significantly better survival (5-year survival of 
approximately 70%) than HPV-negative patients (5-year survival of approximately 35%) 
(Fakhry et al., 2008; Klozar et al., 2008; Vidal & Gillison, 2008). A prospective multicentric 
study has shown that individuals presenting HPV-positive OPCs had better response rates 
to chemotherapy than individuals with no HPV infection (Fakhry et al., 2008). Numerically, 
in the same study, the overall 2-year survival rate for those presenting HPV-positive tumors 
was 95% (95% CI = 87%-100%), compared with a 2-year survival rate of 62% (95% CI = 49%-
74%) for those without HPV infection (Henessey et al., 2009). In other multicenter 
prospective trials evaluating treatment responses in oropharyngeal or laryngeal carcinomas, 
the HPV-positive OPCs were found to have higher response rates to chemotherapy (82% 
versus 55%) than HPV-negative cases (Fakhry et al., 2008). Other similar findings have been 
obtained in treatment response to radiotherapy associated with the presence and titer of the 
high-risk HPV 16 (Dayyani et al., 2010; Vidal & Gillison, 2008). This improved survival is 
more pronounced in OPCs (Dayyani et al., 2010; Hannisdal et al., 2010), and even in 
investigations with no significant associations, there is a tendency toward HPV positivity in 
patients with longer survival.  
Although the improved prognosis conferred by HPV seems to be independent of the 
treatment strategy, the mechanism responsible for this survival difference is still unclear. 
Several hypotheses have been proposed, which include the fact that patients presenting 
HPV-related HNSCCs are usually non-smokers and non-drinkers and do not show 
comorbid disorders. Moreover, despite the lack of conclusion regarding the correlation of 
HPV positivity in some HNSCC sites with p53 status, an enhanced radiosensitivity of HPV-
positive tumors due to an improved apoptotic response secondary to the absence of 
mutations in TP53 of HPV-positive tumors has been proposed, as has immune surveillance 
to viral-specific tumor antigens (Vidal & Gillison, 2008) and lack of field cancerization 
characteristics of individuals with tobacco- and alcohol-related HNSCCs (Hennessey et al., 
2009). 
12. Our results regarding HPV infection in Brazilian oral squamous cell 
carcinoma patients 
The true prevalence of HPV DNA in OSCC and its role as a possible oncogenic agent are 
still controversial. We performed a study that aimed to investigate the HPV frequency in 
Brazilian patients with OSCC in order to establish a clinicopathological profile and its  
possible influence on prognosis (Oliveira et al., 2008). We examined the correlation between 
patient survival and HPV expression in primary tumors (PTs), and their matched samples 
(MSs) of recidives, lymph nodal metastasis (LNM) or necropsies. Eighty-seven PTs and  
their corresponding 87 MSs were tested for HPV infection through PCR using general and 
type-specific HPV primers. For HPV DNA detection, we utilized the GP5+/GP6+  
(Bioneer Inc.) consensus general primer pair to amplify a 150-bp fragment from the L1 gene of 
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general HPV types (GP5+, 5'-TTTGTTACTGTGGTAGATACTAC-3'; GP6+, 5'-
GAAAAATAAACTGTAAATCATATTC-3'). After, PCR was then performed on the  
HPV-positive DNA samples to determine if they contained genotypes 16 and 18, using  
specific primers targeting ~100 bp in the E7 ORF: HPV-16E7.667 (5'-
GATGAAATAGATGGTCCAGC-3'), HPV-16E7.774 (5'-GCTTTGTACGCACAACCGAAGC-
3'), HPV-18E7.696 (5'-AAGAAAACGATGAAATAGATGGA-3') and HPV-18E7.799 (5'-
GGCTTCACACTTACAACACA-3') (Bioneer Inc.). Of the 87 patients investigated, 17 (19.5%) 
were found to have HPV DNA in their tumors. An investigation of all the paraffin-embedded 
specimens revealed the presence of HPV DNA in 18 of the 174 samples (10.4%), 10 (11.5%) 
from PTs and 8 (9.2%) from MSs. Notwithstanding, no virus infection was detected in the 
corresponding PT of 7 (8.1%) MSs, and only a patient demonstrated HPV DNA positivity in 
both samples. The HPV genotypes 16 and 18 were detected in 4 (22.2%) and 3 (16.7%) of the 
positive samples, respectively. Infection with both genotypes was found in 6 (33.3%) 
investigated samples, and the HPV genotype was unidentified in 5 (27.8%) samples. The 
tongue was the most prevalent infected anatomical site. Our main result was a significant 
number of positive HPV samples among non-smoking patients, and albeit a possible influence 
of HPV on tumoral induction cannot be ruled out, the low frequency of HPV positive OSCC 
cases found in our investigation does not suggest that this virus has the same etiological 
influence on patients as tobacco consumption does, and although we cannot rule out a 
possible transient role for HPV in the induction of OSCC, we think that the occasional 
detection of HPV in OSCC resulting from the incidental colonization of tumoral lesions might 
reflect the true involvement of HPV in most investigations. 
13. HPV vaccine 
In many countries, vaccines against some HPV types are administered to girls and young 
women with the goal of protecting them against HPV-induced cervical cancer (Villa et al., 
2005; Muñoz et al., 2010). The introduction of HPV vaccines has also drawn more attention 
to the fact that HPV is associated not only with cervical cancer and genital warts but also 
with other tumors, such as head and neck and anogenital cancers (Zur Hausen, 2006). 
Although the majority of HPV vaccine research has focused on cervical cancer, some vaccine 
developers have targeted other diseases related to different strains of HPV, including two 
types of HPV (6 and 11) that can cause genital warts and recurrent respiratory 
papillomatosis in the larynx. Vaccines against these other strains have attracted the interest 
of vaccine developers because these vaccines may qualify for orphan drug status and fast-
track licensing in the United States (Nventa Biopharmaceuticals Corporation, 2005; Path, 
2006). 
Emerging results from vaccine trials have suggested that some cross-protection is possible. 
Vaccines against cervical cancer also have the potential to prevent other cancers that are 
caused by the same types of HPV, including a subset of head and neck cancers (notably the 
OPC) (Herrero et al., 2003, Kreimer et al., 2005), and half or more of anogenital cancers 
outside the cervix, including cancer of the vulva, vagina, penis, and anus (Daling et al., 2005, 
Gross & Pfister 2004). Theoretically, these vaccines should also work against the same 
viruses at other anatomical sites. If proven to do so, this approach would represent a major 
conceptual breakthrough, not only in prevention of these diseases, but equally importantly, 
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by providing the ‘missing link’ in the chain of evidence for the final proof of HPV etiology 
of these tumors (Syrjänen, 2010). 
13.1 Types of HPV vaccines 
The development of prophylactic and therapeutic vaccines targeting HPV antigens for the 
control of tumors caused by HPV is increasing worldwide. These upcoming vaccines are 
part of a new generation of vaccines that employ genetic engineering, using the ability to 
manipulate and transfer genes from one organism to another (Path, 2006).  
Prophylactic vaccines work primarily by stimulating humoral immunity and inactivating 
HPV before the virus infects the host cells (Zinkernagel, 2003). This strategy requires high 
levels of antibodies at mucosal surfaces over long periods of time (Path, 2006). Maintaining 
these high levels is difficult, so it is recommended that prophylactic vaccines should also 
stimulate a cellular immune response that is capable of eliminating early stages of infection 
in host cells (Duggan-Keen et al., 1998; Galloway, 1998). 
In contrast, therapeutic vaccines aim to generate cell-mediated immune responses using 
killer T cells that actively destroy HPV-infected cells and may exert immediate effects on 
lowering HPV-related disease incidence. To be effective, therapeutic HPV vaccines must 
prompt cell-mediated immunity because antibodies cannot reach and eliminate the virus 
once it has been incorporated into host cells (Ling et al., 2000; Chu, 2003; Maclean et al., 
2005). This type of vaccine could help people who are already infected with HPV. Used 
alone or in combination with standard therapies, a therapeutic vaccine could help prevent 
the progression of low-grade disease and cause existing lesions to regress, avoiding the 
recurrence of cancer lesions after treatment (Chu, 2003; Stanley, 2003).  
In a broad revision, Path (2001) described the existence of five types of HPV vaccines: 
recombinant live vector vaccines; protein and peptide vaccines; virus-like particles (VLPs); 
“naked” DNA vaccines; and edible vaccines (in which plants are genetically engineered to 
express HPV antigens in fruits and vegetables, leading to immunization through ingestion 
of the modified foods).  
The following three categories of HPV proteins represent potential targets for vaccines, each 
of which is expressed during different stages of infection and disease: 
1. The capsid proteins L1 and L2 compose the outside coat of HPV particles. These 
proteins interact with the surface molecules of epithelial cells during early stages of 
infection to gain entry for the viral DNA. Because L1 and L2 are present during the 
initial infection, they are ideal targets for a prophylactic vaccine (Lowy & Schiller, 1998). 
However, once HPV has integrated into the tumor cells, the capsid proteins are not 
always present and they are not reliable targets for a therapeutic vaccine. 
2. The oncoproteins E6 and E7 continue to be expressed during later stages of disease and 
are the primary targets of therapeutic vaccines. These proteins bind the human tumor 
suppressor genes p53 and pRB (Duggan-Keen et al., 1998) and are involved in the 
malignant transformation of HPV-infected cells (Van Driel et al., 1999).  
3. The proteins E1 and E2 are necessary for HPV replication within cells before the virus 
integrates into the host DNA (Duggan-Keen et al., 1998; Van Driel et al., 1999). Because E1 
and E2 are expressed at higher levels than E6 and E7 at the early stages of HPV infection, 
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they may represent the best targets for a therapeutic vaccine designed to treat the early 
stages of disease, such as low-grade dysplasias (Tindle, 1996; Lowy & Schiller, 1998). 
13.2 The HPV prophylactic vaccines 
The current HPV prophylactic vaccines are based on VLPs (Van Monsjou et al., 2010). At 
present, two prophylactic HPV vaccines are commercially available: the bivalent (HPV 
16/18) vaccine Cervarix® (GlaxoSmithKline, Middlesex, UK) and the quadrivalent (HPV 
6/11/16/18) Gardasil® (Merck, NJ, USA). Licensed globally, these two vaccines have 
produced great expectations that they will prevent infections and tumors induced by 
different HPV types (Syrjänen, 2010). 
The US Food and Drug Administration (FDA) approved Gardasil for females ages 9–26 in 
2006. In October 2009, the FDA approved Cervarix for use in females ages 10–25 and 
approved Gardasil for use in males ages 9–26 to prevent genital warts and to prevent the 
spread of cervical cancer. Moreover, the FDA (2010 and 2010a) has proclaimed that the 
dosing and administration schedule should be 0.5 mL administered intramuscularly 
(preferably in a deltoid muscle) on a 3-dose schedule. The second dose should be 
administered 1 to 2 months later, and the third dose should be administered 6 months after 
the first dose.  
These vaccines target the HPV major capsid protein L1 and can assemble to form VLP 
morphologically resembling native virions to generate robust antibody responses and 
prevent HPV infection. However, Gardasil and Cervarix differ in their adjuvants, which are 
substances added to a vaccine to enhance its impact by stimulating immune responses. In 
Gardasil, each type of VLP is purified and adsorbed on an aluminum-containing adjuvant 
(amorphous aluminum hydroxyphosphate sulfate), which is widely used. In contrast, 
Cervarix is formulated with a novel adjuvant, AS04, developed by the Corixa Corporation to 
strengthen and prolong the immune response to vaccines. Like aluminum hydroxide, AS04 
includes MPL® (3-deacylated monophosphoryl lipid A), which is a derivative of the lipid A 
molecule found in gram-negative bacteria and a potent immune system stimulant because it 
primes innate immunity and may stimulate adaptive immunity and enhance antibody titers 
(Ma; Roden; Wu, 2010). 
Although clinical trials of Gardasil and Cervarix have been extremely promising, these first 
generation VLP vaccines may not be the ideal vaccine candidates, especially in low-resource 
settings. Researchers are now actively working to develop other prophylactic HPV vaccines 
that may be effective against a broader range of HPV types and have a longer shelf life. 
13.3 The HPV therapeutic vaccines and its perspectives  
Immunotherapy offers an attractive alternative treatment strategy because it can address 
both the underlying HPV infection and the visible lesions. Moreover, immunotherapy can 
target all HPV-associated lesions, regardless of location, and induce long-lasting immunity, 
thus preventing recurrence (Chu, 2003; Stanley, 2003).  
A judgment of whether therapeutic HPV vaccine candidates have a real effect on disease has 
been difficult because most trials have not been placebo-controlled. The vaccines have also 
shown, at best, limited efficacy in eradicating established tumors, although the fact that they 
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have mostly been tested in advanced stage cancer patients with compromised immune 
systems may have limited their impact (Brinkman et al., 2005).  
Perhaps the most effective HPV vaccine strategy calls for a vaccine that possesses both 
prophylactic and therapeutic properties. A chimeric vaccine of this type could both prevent 
new HPV infections and clear existing infections. Moreover, such a vaccine would benefit 
and could be administered to both sexually inexperienced young individuals and older 
individuals who already harbor HPV (Franceschi, 2005). Opportunities for primary and 
secondary prevention should be assessed, including the use of HPV vaccines to prevent 
infection and therapeutic vaccines in the adjuvant setting for locoregional recurrence and 
distant disease (Marur et al. 2010). Combined with the fact that no therapeutic vaccines 
currently exist for other diseases, this goal makes therapeutic HPV vaccine development a 
challenging task.  
The eventual routine of HPV prophylactic vaccination will most likely have an impact not 
only on the incidence of cervical and anogenital cancers in women and men but also on the 
incidence of some groups of head and neck tumors, as in OPC. The increasing proportion of 
HPV-positive head and neck cancers underlines the increasing importance of routine 
prophylactic vaccination against HPV, and together with tobacco and alcohol control, this 
vaccination could have a decisive position in the prevention of head and neck cancer (Klozar 
et al., 2010). Vaccines directed against HPV 16, which accounts for 80–90% of all HPV-
positive HNSCC, currently exist in Europe and USA (Dahlstrand & Dalianis, 2005; Sturgis & 
Cinciripini, 2007; Hammarstedt et al., 2006; Lindquist et al., 2007; Mellin et al., 2002; Gillison 
et al., 2008; Ang et al., 2010; Marur et al., 2010; Näsman et al., 2009; Attner et al., 2010).  
14. Final considerations 
Several aspects still remain to be discovered in the field of head and neck cancers and HPV 
infection, but the epidemiological analysis of the last decade demonstrates a rapid increase 
in the incidence of HPV-associated HNSCCs, and sufficient evidence now exists for a causal 
role of HPV in HNSCC. The genomic detection of HPV DNA, primarily in OPCs, provides 
stronger support for a viral etiology in HNSCC. Although some synergies between HPV 
oncogenes and other carcinogens have been hypothesized, non-smoking and non-drinking 
patients and those who sexually debut at a younger age have an increased risk of HPV-
positive HNSCCs but show a favorable prognosis. Specifically in oral mucosa, some authors 
have suggested that the occasional finding of HPV DNA in OSCC specimens might not 
result from viral infection but rather from an incidental HPV colonization. However, a 
relative HPV contribution to oral carcinogenesis may occur in a subgroup of patients, 
mainly in areas where tobacco use is less common. 
Targeted therapy for HNSCCs now demands more predictive biomarkers, such as the HPV 
infection status and mutation status of crucial genes, which could contribute to personalized 
treatment for individual patients and decrease the inherent morbidities. However, for a 
better understanding of whether the HPV status of tumors has real therapeutic implications 
in affecting the clinical outcome, upcoming clinical trials should be significantly 
standardized in their design and performed on HNSCCs that have been adequately selected 
and classified with respect to the different head and neck anatomical sites. Moreover, we 
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suggest that other methodologies should be utilized to improve HPV detection and that 
additional population studies should be performed to confirm these findings. 
We believe that the increasing proportion of HPV-positive HNSCCs highlights the 
importance of vaccination against HPV. Although detection of the true effects of HPV 
vaccination on cancer incidence will probably continue for several decades, monitoring the 
current effects of HPV vaccination is crucial, not only in cervical cancer, but also in head and 
neck cancer. 
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